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Abstract: Endocrinological changes that occur with menopause lead to a chronic and
progressive condition named vulvar and vaginal atrophy (VVA). This disease is characterized
by symptoms such as dryness, dyspareunia, itching, burning, and dysuria. According to recent
epidemiological studies, VVA has a high prevalence and can also occur in younger women
prior to the menopause, negatively affecting quality of life, sexual function, intimacy and
relationship with the partner. Accordingly, therapy should be effective, initiated early and
continued for as long as possible. Up to recent years, available therapeutic options have
included over-the-counter lubricants and moisturizers, vaginal oestrogens and systemic hor-
mones. These products are not indicated for all women. Hormones are mostly contraindicated
in women with a history of hormone-sensitive cancer and are frequently not accepted even by
women without contraindications. Local therapies are frequently considered uncomfortable,
difficult to apply, and messy. Indeed, these treatments have a high spontaneous discontinuation
rate, mostly due to dissatisfaction, safety concern, side effects and difficulty in vaginal
placement. Recently, ospemifene, a new non-hormonal systemic remedy, was approved by
FDA (Food and Drug Administration) and EMA (European Medicines Agency) for the
treatment of the two most bothersome symptoms of VVA: dryness and dyspareunia. Because
ospemifene is a selective estrogen receptor modulator (SERM), it can be administered also in
women with a history of breast cancer, and this makes it more acceptable by any woman. In
addition, its route of administration minimizes those bothersome side effects intrinsic to the
vaginal route of administration. Available data indicate that women using ospemifene have
higher adherence to treatment, higher persistence and lower discontinuation rate. Satisfaction is
higher than with other local therapies and overall health care cost is lower.
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Introduction
Vulvar and vaginal atrophy (VVA) is a chronic and progressive disease character-
ized by anatomical-functional alterations caused by aging and hypoestrogenism.1
Since 2014, VVA is considered part of the genitourinary syndrome of menopause
(GSM).1 Anatomical changes of VVA (i.e. thinning of vaginal rugae, mucosal dryness,
pallor, fragility, and the presence of petechiae)2 develop gradually during years and do
not resolve spontaneously. Hypoestrogenism leads to an atrophy of the vaginal, vulvar,
urethral and bladder epithelium. Consequently, the vaginal maturation index (VMI), i.e.
the ratio among three different vaginal epithelial cell types, parabasal, intermediate, and
superficial, changes towards a predominance of parabasal cells. Glycogen production
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decreases, vaginal microbiota changes, vaginal pH increases
above 4.5, and risk of vaginal infection increases.3,4 Related
symptoms are dryness, dyspareunia, itching, burning, and
dysuria.
In European countries, prevalence of postmenopausal
VVA is around 80%.5,6 Noteworthy, 65% of women
experience VVA within one year since menopause.
Symptoms and signs of VVA occur also in younger
women, prior to the menopause. An Italian study,7 per-
formed in a cohort of women aged between 40 and 55
years observed a prevalence of VVA and of vaginal dry-
ness of 36.8% and of 64%, respectively.
Vaginal dryness and dyspareunia are the most bother-
some symptoms of VVA.8,9 These symptoms can affect
sexuality, intimacy, overall pleasure, sexual satisfaction,
relationship with a partner, the seeking of a new relation-
ship and, ultimately, emotional health and woman’s quality
of life.10–13
Diagnosis of VVA can be simple: the criteria of a large
multicentric Italian study (AGATA study) indicate that the
concomitance of a pH>5, sensation of vaginal dryness and
an objective index at the examination (thinning of vaginal
rugae, mucosal dryness, pallor, fragility, and the pete-
chiae), is enough to make diagnosis. Anyway, diagnosis
can be even easier because, as shown in epidemiological
studies, all postmenopausal women with VVA suffer from
vaginal dryness and dryness alone, without VVA, is pre-
sent only in a small percentage of cases ranging from 3 to
10%.4,6 Thus, the only presence of vaginal dryness can be
sufficient for the diagnosis of postmenopausal VVA.
Vaginal dryness is also the most bothersome symptom
and its presence is sufficient to start a therapy.
Therapeutic options include local and systemic hormo-
nal and non-hormonal products, ranging from over-the-
counter lubricant and moisturizers to medications such as
vaginal oestrogens (cream, tablets and ring), systemic hor-
mones and the innovative oral selective estrogen receptor
modulator (SERM): ospemifene.14,15
Therapeutic Options
First-line therapies for women with symptomatic VVA
include intercourse that can be associated with non-
hormonal lubricants and regular use of long-acting vaginal
moisturizers or vaginal estrogen.14,16 Therapy should be
started early, before irreversible atrophic changes have
occurred, and should be continued for as long as
possible.17 Systemic hormones are an effective therapy,
but they are recommended only to eligible women that
beyond VVA suffer from menopausal complaints (e.g.
vasomotor symptoms).3,17
Over-the-counter vaginal lubricants and moisturizers are
often prescribed as a first-line treatment and are indicated in
women with a previous history of hormone-dependent can-
cers. Unfortunately, they may provide only a transient benefit
of vaginal symptoms in comparison to local oestrogens.18
Vaginal lubricants are intended to be used to relieve friction
and dyspareunia and are applied to the vaginal introitus before
sexual intercourse. Water-based lubricants are the most com-
mon, probably because of their wide availability and low
price. Unlike oil or silicone lubricants, they do not stain sheets
or lingerie. According to a recent review,19 water-based lubri-
cants should have an acidic pH (pH 3.8–4.5) and an osmolarity
below 380 mOsm/kg. This is to preserve the vaginal micro-
environment and to reduce cytopathic or irritating effects on
the vaginal mucosa. Lubricants based on silicone are not
absorbed by vaginal mucosa; therefore, they persist longer.
A recent study reported that during sexual intercourse, sili-
cone-based lubricants might reduce total sexual discomfort
more effectively than water-based products.20
Vaginal moisturizers, rather than lubricants, are locally
absorbed by superficial layers, rehydrate dry mucosal tissue
and have a long-term action. Specifically, the beneficial
effects of vaginal moisturizers are mostly due to adhesive
and buffering capacities leading to tissue water retention and
vaginal pH reduction.21 Polycarbophil basedmoisturizers are
as effective as vaginal oestrogen therapy in reducing post-
menopausal VVA symptoms22,23 but not in improving sexual
function and menopause-related quality of life.24
Low dose local oestrogens, in the form of cream,
tablet, or ring are all effective for VVA symptoms, with
a minimal systemic absorption. Thus, vaginal oestrogen
products seem to be safe with only a few adverse effects.25
A review including 44 published studies did not report any
case of either thromboembolism or breast cancer.
Nevertheless, data on long-term efficacy, risks, and toler-
ability are limited because most reported studies have
a follow-up period of only 12 weeks.26
Adherence to Local Treatments
Epidemiological studies have shown that most women dis-
continue vaginal therapy. The reason for discontinuation is that
they are uncomfortable, difficult to apply, and annoying.9,13 In
addition, many women claim a non-sufficient therapeutic effi-
cacy, either for an excessive expectation or an inadequate
dose-regimen.9 Indeed, the different types of vaginal treat-
ments are prescribed without a clear rationale, a clear dose
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and scheme, and a clear indication on duration. This situation
is further prompted by the absence of clear guidelines on
therapeutic cycles, dosages and duration.9 According to
a study published in 2013, many women treated with vaginal
oestrogens reported missing doses at least once a month, often
because of messiness when filling and inserting the applicator,
general unpleasantness of the cream, the need to wash the
applicator and leakage of the cream following application.27
Ospemifene an Innovative Option
Recently, ospemifene, a new non-hormonal drug, was
approved for the treatment of VVA symptoms. Ospemifene
is a third-generation selective estrogen receptor modulator
(SERM), that is administered orally at the dose of 60 mg
daily. It was initially approved by the FDA28 and endorsed
by the North AmericanMenopause Society15 for the treatment
of moderate and severe dyspareunia associated with VVA.
Following the recent publication of a new clinical trial,29
ospemifene has been approved also for the treatment of mod-
erate to severe vaginal dryness. In Europe, the European
Medicines Agency (EMA) has approved ospemifene for the
treatment of all VVA symptoms, from moderate to severe.
Ospemifene is targeted for acting, as an agonist, in the vulva
and vagina, without exertingmajor side effects in other organs.
Through oestrogen receptors stimulation, ospemifene pro-
motes proliferation of the vaginal mucosa epithelial lining.30
Ki-67 immunoreactivity, an index of cell proliferation,
increases enormously in the basal layers of the mucosa,
sampled both in the upper and the lower third of the
vagina.30 The effect is noticeable also on vaginal collagen.
Administration of ospemifene increases total collagen both in
vaginal mucosa and vestibule. The preferential augmentation
of type I rather than type III collagen, increases strength and
resistance of vaginal tissue.31 Efficacy and safety of ospemi-
fene was established in randomized, placebo-controlled, Phase
II/III studies.32–35 After only four weeks, administration of
ospemifene increases superficial cells and decreases parabasal
cells and vaginal pH. Concomitantly, VVA symptoms and
sexuality improve.29,32–35 Data on tolerability are confirmed
by a recent post-hoc analysis documenting a low drop-out rate
(7.6% with ospemifene and 3.8% with placebo).36
At the vulva and vaginal vestibule, ospemifene reduces
painful transmission of C-type nerve fibres that convey pain-
ful stimuli37 and exerts trophic effects. Administration of
ospemifene for 20 weeks reduces urethral meatus and ante-
rior vaginal wall prominence, stenosis of the introitus, ves-
tibular pallor and erythema and ameliorates vulvar
moisture.38 Modifications are associated with improvement
of cotton-tipped swab testing and sexual function.37 Pain at
intercourse decreases, while desire and arousal increase.39,40
Ospemifene vs Vaginal Oestrogens:
Safety
VVA is a chronic and progressive disease and it would
require long-term therapy. Unfortunately, adherence to
treatment is weak and many women discontinue vaginal
therapy for perceived inefficacy, inconvenient administra-
tion or perceived risk.
Several studies focused on safety, specifically on the endo-
metrium, breast and coagulation. There is no direct compar-
ison between ospemifene and vaginal oestrogens, but, from
the analysis of the literature, a historical indirect comparison
can be tentatively performed (Table 1). Endometrial safety of
the two treatments appears to be comparable with no evidence
of an increased risk of cancer. Simon et al41 described one
event of endometrial carcinoma and one case of complex
hyperplasia without atypia in postmenopausal women treated
for 52-weeks with an ultra-low-dose (10-microgram) of 17β-
oestradiol in vaginal tablets. In a multicentre randomized,
double-blind Phase 3 study, one case of simple hyperplasia
without atypia and no case of endometrial carcinoma was
diagnosed three months after the last administration of a 12-
week ospemifene treatment.35 Long-term studies, up to 52
weeks of administration, show no effect of ospemifene on
the endometrium.33,42
Oestrogens administered into the vagina are partially
absorbed, slightly increasing systemic exposure. For this
reason, they are considered potentially harmful for breast
cancer, although there is no evidence of an increased rate
of breast cancer during or after their administration.43
In vitro, ospemifene exerts anti-oestrogenic effects in the
ER+ MCF-7 breast cancer cells by inhibiting, in a dose-
dependent manner, the oestrogen-regulated gene expression
of pS2.44 The same findings are observed in ovariectomized
mice in vivo, where ospemifene reduces growth of MCF-7
cancer cells. In comparison to control, administration of
Table 1 Safety of Ospemifene and Vaginal Oestrogens on the
Risk of Hormone-Dependent Cancer, Venous Thrombosis (VTE)
or Cardiovascular Disease (CVD). Summary of the Literature
Ospemifene Vaginal Oestrogens
Endometrial Cancer Safe Safe
Breast Cancer Safe Unclear
VTE Safe Safe
CVD Safe Safe
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ospemifene inhibits MCF-7 tumour growth, with a difference
in volume that become significant after only 3 weeks of
treatment.44 Similar data are shown in another study after
only 4 weeks of ospemifene administration.45
In vitro and in animals’ results were replicated on
breast tissue, collected from 26 healthy postmenopausal
women undergoing reductive mammoplasty. In this model,
ospemifene significantly inhibits oestrogen-induced cell
proliferation.46 Clinical data are also reassuring.
Safety of ospemifene on breast was evaluated in a post-
hoc analysis of six Phase 2 and 3 clinical trials.36 A total of
2200 postmenopausal womenwere randomized either to ospe-
mifene or placebo for amedian duration of treatment of 86 and
84 days, respectively. Breast safety was evaluated by both
mammography, performed prior to treatment and after 12
months, and breast palpations performed prior to treatment,
at 12 weeks, six months, and 12 months. No case of breast
cancer was observed. Prevalence of adverse events such as
breast tension (0.9% vs 0.6% for placebo), pain (0.6% vs
0.3%), and breast thickening (0.6% vs 0.4%), were similar in
the ospemifene and placebo group (2.5% vs 2.2% for
placebo).36 Breast density was not assessed. However, no
other abnormal clinically significant mammogram findings
were reported, and the prevalence of abnormal not clinically
significant findings was similar between ospemifene and
placebo.36 Based on these preclinical and clinical data, ospe-
mifene is the only VVA therapy that stimulates oestrogen
receptors at the vagina, that can be prescribed to women
with a history of breast cancer, after the termination of adju-
vant treatment.47
Systemic estrogens48 and SERMS, such as raloxifene or
tamoxifen,49–51 increase the risk of venous thromboembolism
(VTE). VTE is not increased by vaginal estrogens.43 Also
ospemifene does not increase the risk of VTE. In a post-hoc
analysis of 6 Phase II and Phase III studies the incidence of
cardiovascular events (i.e. specifically deep vein thrombosis,
cerebrovascular accidents, and cerebral haemorrhages) was
shown to be very low, both in the ospemifene (0.3%) and
placebo (0.1%) group.36 In this latter analysis, only two high-
risk patients reported VTE during ospemifene, with no case of
pulmonary embolism or retinal vein thrombosis. A recent post
hoc analysis of five placebo-controlled clinical studies showed
that, in comparison to placebo, ospemifene, up to 12months of
use, decreases fibrinogen, a known risk factor for coronary
artery disease and VTE and, similarly to oral oestrogens,52 it
increases HDL and reduces LDL.53 Differently from oral
estrogens,52 ospemifene does not increase triglycerides.53 In
a post-marketing observational analysis of the 2-year interim
data of the Post Authorisation Safety Study (PASS), the inci-
dence of VTE in the group of women receiving ospemifene
(0.12%) is lower than that of women receiving other SERMS
for non-neoplastic reasons (0.64%), or of women with AVV
not receiving any treatment (1.23%).54 No increased risk of
cardiovascular diseases, breast tumours, endometrial hyperpla-
sia, or gynaecological pathologies of any kind is also
observed.54
Ospemifene vs Vaginal Oestrogens:
Side Effects
Adverse events were reported for both types of treatment,
including hot flushes, vaginal discharge, muscle spasms,
and headache (Table 2). Among women treated with ospe-
mifene, hot flushes were the most reported adverse event
(7.5% vs 2.6% for placebo) and, although low, the most
common reason for discontinuation (1.0%).36 Frequency
and intensity of hot flushes was higher during the first four
weeks of treatment and decreased subsequently with con-
tinuous use.55 These symptoms were observed also with
vaginal oestradiol, but with an incidence below 1%.56
Vaginal discharge or discomfort were reported in up to
10% of patients treated with vaginal estradiol.43,56 Simon et al
reported that one of the most common treatment-related
adverse events during ospemifene was vaginal discharge
(3.8% vs 0.3% for placebo) but this led to treatment disconti-
nuation only in 0.5% of patients.36
As noted with other SERMs, muscle spasms are com-
monly reported from women using ospemifene (3.2% vs
0.9%)36 and are generally described as mild or moderate leg
cramps. This side effect was never reported with local
estrogen.43 Headache was reported with the same frequency
during placebo or ospemifene (2.4% vs 2.4%)36 whereas its
Table 2 Risk of Side Effects, Discontinuation Rate, Adherence
to, Satisfaction with and Overall Related Cost of Treatment with
Ospemifene or Vaginal Oestrogens. Summary of the Literature
Ospemifene Vaginal
Oestrogens
Hot Flushes Slight None/Slight
Vaginal Discharge Slight High
Headache Slight Moderate




Overall Health-Related Cost Lower Higher
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incidence tended to be higher ranging from 1 to 10% during
the use of vaginal estrogens.43,56
Therefore, ospemifene and local oestrogens appear to
have a similar tolerability, but acceptability, adherence to
treatment and discontinuation may differ as the conse-
quence of the different pharmaceutical formulation and
route of administration (Table 2).
Ospemifene vs Vaginal Oestrogens:
Adherence to Treatment and
Satisfaction
One study evaluating adherence to treatment with vaginal
oestrogens reported that users of these formulations miss
a dose at least once a month, often because of messiness,
general unpleasantness of the cream, the need to wash the
applicator and leakage of the cream following application.27
Adherence to treatment, i.e. the number of days covered by
therapy out of the number of total days considered, was
recently evaluated in a 12-months study, comparing ospemi-
fene and vaginal oestrogens. The study was performed in
86,946 patients with more than one pharmacy claim for dys-
pareunia-related medication.57 Highest adherence was
observed for ospemifene in comparison to non-ring local hor-
monal therapy e.g. conjugated oestrogen cream, oestradiol
vaginal insert, and oestradiol cream (40% vs 21%;
p<0.0001). Only the ring showed a higher adherence to treat-
ment (52%). Persistence (ie appropriate time of drug refill) was
also higher for ospemifene than vaginal creams (23% vs
4–16% of vaginal cream; p<0.0001). The ring had the highest
treatment (44%) persistence. Discontinuation rate of ospemi-
fenewas 77.1%, and itwas significantly lower (P<0.0001) than
that of oestradiol vaginal insert (83.6%), conjugated oestrogen
cream (95.0%), and oestradiol cream (93.7%). The vaginal
ring had the lowest discontinuation rate (56.4%). On these
bases ospemifene can be considered superior to vaginal oestro-
gens but not to the vaginal ring, in terms of adherence, persis-
tence and treatment continuation. However, the ring does not
have the indication to the treatment of dyspareunia, that ospe-
mifene has.58 Furthermore, health-care cost, that take into
consideration the cost of the product and of medical consulta-
tions over a period of 12 months, are higher for the ring, and
vaginal oestrogens, than for ospemifene. The cost of ospemi-
fene is higher than that of local hormonal therapies, butmedical
consultations are less for women on ospemifene than other
therapies. This indirectly supports a higher efficacy and toler-
ability of ospemifene vs any type of vaginal treatment,
probably consequent also to a greater adherence and persis-
tence to treatment.
Finally, when using the ring, women are concerned about
inserting or removing it, about vaginal infections, hygiene
and cleanliness, about the oestrogen dose administered, and
about feeling it.27 A recent survey evaluated woman’s per-
ceptions of VVA and its therapeutic options.59 Symptomatic
women above 45 years of age were invited to complete
a survey containing 63 questions related to VVA symptoms,
menopausal status, therapeutic options, way of prescription,
efficacy, and acceptability. Among 1858 women that
completed the survey, 7% were “current users” of
a pharmaceutical therapy for VVA (including vaginal oestro-
gen or oral SERMS), 18% were “former users” of that
therapy, 25% were current or former users of over-the-
counter (OTC) products like vaginal lubricants or moistur-
izers, and 50% had never used any therapy (“never users”).
Most recommended treatment in current or former users was
vaginal oestrogen and oral hormones, but, among those who
had never used any treatment, 35% stated that nothing would
convince them to use hormones. Fear of using hormones and
discomfort with the application make local hormonal treat-
ments hardly accepted by women.59 Fear of systemic absorp-
tion and inconvenient administration of local creams,
reduced adherence to treatment. Only few women (33-
42%) used more than once per week vaginal oestrogens
that were prescribed “continuously”, and 75% of women
used moisturizers and lubricants “as needed”, instead of
few times per week. The highest adherence to treatment
was observed in women receiving the daily dose of ospemi-
fene (59%). Satisfaction was also highest with ospemifene,
reaching 67% of users. Satisfaction with lubricants and
moisturizers used “as needed” was only 15% and that with
vaginal oestrogens for creams, tablets or the ring ranged
between 33-35%.59
In conclusion, women’s adherence, persistence and satis-
faction with long-term treatment is higher for ospemifene
than for other products.59 Likely, this is the consequence of
a combination of effectiveness and ease of use. Unlike other
local therapies, ospemifene does not need any scheme of
treatment, just taking a pill per day. Adherence to treatment
is favoured by the oral administration of a non-hormonal
drug that avoids the inconvenience of the local application
of therapies and the fear of hormones.59,60
Conclusion
Ospemifene is the first oral treatment for VVA that provides an
alternative treatment for patients unsuitable for vaginal
Dovepress Cagnacci et al
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products or for oestrogen. Its clinical characteristics give the
opportunity to propose long-term therapies for VVA that have
the possibility to be followed. Ospemifene not only enlarge the
number of women that can be treated for VVA, but also
increases adherence and persistence to treatment.
Accordingly, in the field of the VVA therapy, ospemi-
fene represents an innovative evolution, that can help to
reduce the burden of symptoms and the consequences of
postmenopausal VVA.
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